There are no controlled trials in the treatment of hepatitis C after liver transplant. Recurrent HCV is generally treated only if it is associated with significant histologic liver injury. However, the therapeutic options are limited and rigorous clinical trials are difficult to conduct. In addition to changing immunosuppressive regimens, studies have examined the efficacy of interferon, ribavirin, and combination therapy.
The available data suggest that combination therapy with interferon and ribavirin may be useful in transplant recipients with recurrent HCV. However, there is no consensus on the optimal strategies for administering therapy. Because of the side-effect profile of these drugs many patients are not eligible for treatment or withdraw during therapy.
Other options, including retransplantation, have also been studied, but there does not seem to be a clear benefit over medications.
Again, there is no consensus in cases such as these. You may want to seek the opinion of several hepatologists to evaluate the best option in your case.
Followup with your personal physician is essential.
This answer is not intended as and does not substitute for medical advice - the information presented is for patient education only. Please see your personal physician for further evaluation of your individual case.
Thanks,
Kevin, M.D.
Bibliography:
Chopra et al. Liver transplantation for hepatitis C virus infection. UptoDate, 2004.